# Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

> **NCT01430195** · PHASE1 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 56 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Afamelanotide
- **PROCEDURE:** Narrow-Band UVB Light Treatment

## Key facts

- **NCT ID:** NCT01430195
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-11
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430195, "Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01430195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*